9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions

Hematologic Emergencies, Anticoagulant Reversal, and Transfusions

Intensivists frequently manage life-threatening bleeding requiring rapid reversal of anticoagulation, as well as complex hematologic disorders and complications of blood product administration.

Anticoagulant Reversal

Life-threatening bleeding (e.g., intracranial hemorrhage, massive GI bleed) while on anticoagulation requires rapid, targeted reversal.

Warfarin (Vitamin K Antagonist)

Warfarin inhibits the Vitamin K Epoxide Reductase (VKOR) enzyme, depleting active Vitamin K-dependent clotting factors (II, VII, IX, X, and Proteins C and S).

• Reversal Agent: 4-Factor Prothrombin Complex Concentrate (4F-PCC) + IV Vitamin K.
• Mechanism: 4F-PCC (Kcentra) contains concentrated factors II, VII, IX, and X, providing immediate repletion. Vitamin K (5-10 mg IV) takes 12-24 hours to synthesize new factors and is given to sustain the reversal once the 4F-PCC wears off.
• Alternative: Fresh Frozen Plasma (FFP) can be used if 4F-PCC is unavailable, but it requires large volumes (risk of volume overload/TACO), requires thawing time, and is less effective at rapidly correcting the INR.

Direct Oral Anticoagulants (DOACs)

DOACs target specific factors in the coagulation cascade.

• Direct Thrombin (Factor IIa) Inhibitor: Dabigatran
  • Reversal: Idarucizumab (Praxbind). A monoclonal antibody fragment that binds to dabigatran with much higher affinity than dabigatran binds to thrombin.
• Factor Xa Inhibitors: Apixaban, Rivaroxaban
  • Reversal: Andexanet alfa (Andexxa). A recombinant, inactive form of factor Xa that acts as a decoy receptor, binding the inhibitor and freeing native factor Xa.
  • Alternative: If Andexanet alfa is unavailable, 4F-PCC (often a fixed dose of 50 Units/kg) is frequently used off-label.

Heparins

• Unfractionated Heparin (UFH) and LMWH (Enoxaparin):
  • Reversal: Protamine sulfate.
  • Dosing for UFH: 1 mg of protamine reverses approximately 100 units of UFH. Because UFH has a short half-life, only the heparin given in the last 2-2.5 hours is calculated. Max single dose is 50 mg due to risks of hypotension, bradycardia, and anaphylaxis.
  • Dosing for LMWH: If given within 8 hours, 1 mg protamine per 1 mg of enoxaparin. Protamine only partially (~60%) reverses the anti-Xa activity of LMWH.

Heparin-Induced Thrombocytopenia (HIT)

HIT is an immune-mediated, prothrombotic adverse drug reaction. IgG antibodies form against the heparin-Platelet Factor 4 (PF4) complex. These antibodies activate platelets, leading to thrombosis (venous > arterial) and subsequent consumptive thrombocytopenia.

Diagnosis:

• 4Ts Score: Evaluates Thrombocytopenia (usually a 50% drop from baseline), Timing (typically days 5-10 after heparin exposure), Thrombosis, and absence of oTher causes. A high probability score warrants immediate empiric treatment.
• Laboratory Testing: PF4 ELISA (high sensitivity, low specificity) followed by a Serotonin Release Assay (SRA, high specificity, the gold standard).

Management:

1. Stop ALL heparin products immediately (including flushes and coated catheters).
2. Initiate an alternative non-heparin anticoagulant, even if no thrombosis is clinically evident, due to the high risk of new clots. Options include direct thrombin inhibitors (Argatroban, Bivalirudin) or Factor Xa inhibitors (Fondaparinux).
   • Note on Argatroban: Hepatically cleared; will falsely elevate the INR.
   • Note on Bivalirudin: Renally cleared.
3. Avoid Warfarin acutely, as it depletes Protein C rapidly and can cause venous limb gangrene in the setting of HIT. Warfarin is only started once platelets have fully recovered (>150,000).
4. Avoid Platelet Transfusions, which can add fuel to the fire (more PF4 to form complexes), unless there is life-threatening bleeding.

Thrombotic Thrombocytopenic Purpura (TTP)

TTP is a medical emergency caused by a deficiency (usually autoimmune) of ADAMTS13, a metalloprotease that cleaves large von Willebrand Factor (vWF) multimers. Uncut multimers cause widespread platelet adhesion and microthrombi in small vessels.

Clinical Pentad: Microangiopathic Hemolytic Anemia (MAHA) with schistocytes, Thrombocytopenia, Neurologic symptoms, Renal failure, and Fever. (The full pentad is rare; MAHA and thrombocytopenia alone warrant suspicion).

Management:

• Therapeutic Plasma Exchange (TPE): The cornerstone of therapy. It removes the autoantibodies and replaces the missing ADAMTS13 enzyme.
• Caplacizumab: An anti-vWF nanobody that blocks the interaction between vWF multimers and platelets, rapidly stopping microthrombus formation.
• Immunosuppression: Corticosteroids and Rituximab to halt autoantibody production.
• DO NOT transfuse platelets unless life-threatening hemorrhage is present, as this exacerbates microthrombi formation.

Massive Transfusion Protocols (MTP) and Transfusion Reactions

MTPs are utilized for severe hemorrhagic shock (e.g., trauma, GI bleed, ruptured AAA). The goal is to simulate whole blood to prevent dilutional coagulopathy.

• Ratio: Most protocols use a 1:1:1 ratio of Packed Red Blood Cells (PRBCs) : Fresh Frozen Plasma (FFP) : Platelets.
• Complications of MTP:
  • Hypocalcemia: Citrate is used as an anticoagulant in stored blood products. Massive citrate loads bind endogenous calcium, causing severe hypocalcemia, which exacerbates hypotension and coagulopathy. Calcium replacement (gluconate or chloride) is essential.
  • Hypothermia: Transfusing cold blood products worsens coagulopathy.
  • Hyperkalemia: Potassium leaks out of RBCs during storage; old blood has high potassium levels.

Transfusion Reactions